Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial. (2019)
Attributed to:
Tuberculosis Treatment Trials
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s2213-2600(19)30366-2
PubMed Identifier: 31732485
Publication URI: http://europepmc.org/abstract/MED/31732485
Type: Journal Article/Review
Volume: 7
Parent Publication: The Lancet. Respiratory medicine
Issue: 12
ISSN: 2213-2600